GREY:IMVIF - Post by User
Comment by
qwerty22on Nov 11, 2020 12:38pm
157 Views
Post# 31877875
RE:12th Nov
RE:12th Nov There's a good discussion here about dlbcl treatment and r/r dlbcl. Lots of extra links.
https://www.emjreviews.com/hematology/symposium/antibody-therapies-for-patients-with-diffuse-large-b-cell-lymphoma-what-does-the-future-hold/
Maybe the section "Polatuzumab Vedotin: Clinical Data in Relapsed/Refractory Diffuse Large B-Cell Lymphoma" Is a useful comparable. Here's the data that supported a recent FDA approval
In the Phase II randomised portion of the trial, baseline characteristics of patients (n=80) were generally comparable between the arms; the median age of participants ranged from 67 to 71 years, and the majority had advanced-stage disease with a duration of response (DoR) to the last treatment of <12 months in 80% of patients. Around 80% were refractory to their prior therapy and approximately 50% in the pola-BR arm were primary refractory. Patients had received a median of two prior therapies (range: 1–7 prior therapies in the pola-BR arm, and 1–5 in the BR alone arm).85,86
Patients were randomly assigned (1:1) to receive pola-BR or BR for six (21-day) cycles. The results of the primary analysis at the 22.3-month follow-up showed that the pola-BR cohort demonstrated significantly higher ORR (45% versus 18%; p=0.008) and CR (40% versus 18%; p=0.026) compared with the BR alone cohort, regardless of prior treatment status (number of prior line of therapy, refractory, or relapse). Significantly longer DoR (median 10.3 months versus 4.1 months; hazard ratio [HR]: 0.44; p=0.0321) and PFS (median 7.6 months versus 2.0 months; HR: 0.34; p=0.0001) were also seen in the pola-BR cohort compared with BR alone. Furthermore, at the time of analysis, seven patients (18%) in the pola-BR cohort continued to have an ongoing response of >20 months duration. The efficacy of pola-BR was observed regardless of COO or DE status.85,86
Updated clinical data with an additional 6 months follow-up has been pooled together with the six patients from the Phase I safety run-in to look at the trends in long-term survival (median follow-up 27.6 months, maximum follow-up 45.9 months). At 24 months, 31.4% of patients had not progressed; 22.0% of pola-BR patients remain in complete remission at last follow-up (ongoing DoR of >20 months), with only one patient having received subsequent therapy (allogeneic transplant)
A path forward like that makes sense.
NordStocks wrote:
What should we be looking for in the presentation tomorrow? The actual data is already presented in the poster, so is there anything specific that they might discuss that could come up as a suprise for us?
Cheers,
Nord